Recursion Pharmaceuticals, Inc. (RXRX) Tops Q4 EPS by 9c

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q4 EPS of ($0.21), $0.09 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $35.54 million versus the consensus estimate of $24.51 million.

For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Home Depot (HD) call put ratio 1.5 calls to 1 put with a focus on September 330 puts into quarter results